Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Samuel Klempner, a GI medical oncologist from the Massachusetts General Hospital, to discuss the evolving treatment landscape for upper gastrointestinal cancers, specifically esophageal, gastroesophageal junction (GEJ), and gastric adenocarcinoma.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9...
Apple Podcast: https://podcasts.apple.com/us/podcast...

Follow us on social media:
•⁠  ⁠X/Twitter: https://x.com/oncbrothers
•⁠  ⁠Instagram: Instagram: oncbrothers
•⁠  Website: https://oncbrothers.com/

During our discussion we touched on:

• The treatment algorithm for localized disease, including the shift from local therapy to a combination of systemic and local treatments
• The current standard of care, which includes perioperative durvalumab with the FLOT regimen and surgery
• The role of chemoradiation therapy for patients who are not surgical candidates and the nuances of managing residual disease
• The importance of biomarker-driven treatment in metastatic disease, focusing on HER2 status, PD-L1 scores, and CLDN18.2 expression
• The latest advancement, the approval of zanidatamab and clinical implications for treatment strategies
• Management of side effects associated with these therapies and the importance of patient quality of life

Whether you're a healthcare professional or someone interested in the latest in cancer care, this episode provides valuable insights into the complexities of treating upper GI cancers.

Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!

#UpperGICancer, #GastricCancer, #Zanidatamab, #Zolbetuximab, #OncologyBrothers